ESC Heart Failure (Apr 2021)

Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome

  • Marijke van derMeulen,
  • Susanna denBoer,
  • Gideon J. duMarchie Sarvaas,
  • Nico Blom,
  • Arend D.J. tenHarkel,
  • Hans M.P.J. Breur,
  • Lukas A.J. Rammeloo,
  • Ronald Tanke,
  • Ad J.J.C. Bogers,
  • Willem A. Helbing,
  • Eric Boersma,
  • Michiel Dalinghaus

DOI
https://doi.org/10.1002/ehf2.13233
Journal volume & issue
Vol. 8, no. 2
pp. 1472 – 1481

Abstract

Read online

Abstract Aims We aimed to determine whether in children with dilated cardiomyopathy repeated measurement of known risk factors for death or heart transplantation (HTx) during disease progression can identify children at the highest risk for adverse outcome. Methods and results Of 137 children we included in a prospective cohort, 36 (26%) reached the study endpoint (SE: all‐cause death or HTx), 15 (11%) died at a median of 0.09 years [inter‐quartile range (IQR) 0.03–0.7] after diagnosis, and 21 (15%) underwent HTx at a median of 2.9 years [IQR 0.8–6.1] after diagnosis. Median follow‐up was 2.1 years [IQR 0.8–4.3]. Twenty‐three children recovered at a median of 0.6 years [IQR 0.5–1.4] after diagnosis, and 78 children had ongoing disease at the end of the study. Children who reached the SE could be distinguished from those who did not, based on the temporal evolution of four risk factors: stunting of length growth (−0.42 vs. −0.02 length Z‐score per year, P 6 years at presentation (all P < 0.001) were predictive of adverse outcome. In multivariate analysis, NT‐proBNP appeared the only independent predictor for adverse outcome, a two‐fold higher NT‐proBNP was associated with a 2.8 times higher risk of the SE (hazard ratio 2.78, 95% confidence interval 1.81–3.94, P < 0.001). Conclusions The evolution over time of NT‐proBNP, LVIDd, length growth, and NYU PHFI identified a subgroup of children with dilated cardiomyopathy at high risk for adverse outcome. In this sample, with a limited number of endpoints, NT‐proBNP was the strongest independent predictor for adverse outcome.

Keywords